Allena Pharmaceuticals
12
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
16.7%
2 terminated/withdrawn out of 12 trials
83.3%
-3.2% vs industry average
17%
2 trials in Phase 3/4
20%
2 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease
Role: lead
An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)
Role: lead
Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets
Role: lead
Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria
Role: lead
A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria
Role: lead
ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers
Role: lead
Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)
Role: lead
Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia
Role: lead
Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria
Role: lead
Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
Role: lead
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones
Role: lead
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days
Role: lead
All 12 trials loaded